Quarterly Updates31 Oct 2025, 01:13 pm
Jubilant Pharmova Reports Strong Q2 & H1’FY26 Results, Showing Revenue Growth and EBITDA & PAT Margin Expansion
AI Summary
Jubilant Pharmova Limited reported its Q2 and H1’FY26 results, showcasing a strong performance with a 12% YoY increase in revenue, driven by incremental revenue generation from the new and third line in the CDMO Sterile Injectable business. EBITDA grew by 13% YoY to Rs. 351 Cr. due to improved performance in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, and CRDMO business. Normalised PAT grew by 21% to Rs. 124 Cr. due to improved operating performance and reduced finance cost. The company is investing in Radiopharma, CDMO Sterile Injectables, and CRDMO business to secure future growth, leading to an increase in Net Debt / EBITDA from 1.1x in Mar’25 to 1.5x in Sep’25.
Key Highlights
- Revenue of Rs. 1,966 Cr. for Q2’FY26, reflecting a growth of 12% on YoY basis
- EBITDA for the period grew by 13% YoY to Rs. 351 Cr.
- Normalised PAT grew by 21% to Rs. 124 Cr. on the back of improved operating performance and reduced finance cost
- Investing in Radiopharma, CDMO Sterile Injectables, and CRDMO business to secure future growth
- Completed the sale and transfer of API Business to Jubilant Biosys Limited